BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, November 27, 2024
See today's BioWorld
Home
» Once upon a time: Avadel, Jazz sleep stories vie in narcolepsy’s new world
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Once upon a time: Avadel, Jazz sleep stories vie in narcolepsy’s new world
Sep. 11, 2020
By
Randy Osborne
No Comments
Investors clipped shares of Avadel Pharmaceuticals plc recently as anxieties rose over the application by Jazz Pharmaceuticals plc for a patent that relates to a once-nightly oxybate product that could threaten the prospects for Avadel’s FT-218.
BioWorld
Clinical
Drugs
Neurology/psychiatric